(redirected from Androgen Deprivation Therapy)
Also found in: Medical.
ADTAndrogen Deprivation Therapy (cancer treatment)
ADTAdult (airline passenger type)
ADTAbstract Data Type (OOP class)
ADTArchitectural Desktop (Autodesk)
ADTAndroid Development Tools (software)
ADTAverage Daily Traffic
ADTAtlantic Daylight Time
ADTAmerican District Telegraph (Boca Raton, FL)
ADTAmerican Dental Trading (various locations)
ADTAustralasian Digital Theses (1998-2011)
ADTAttention Deficit Trait (psychiatry)
ADTApplication Development Trends
ADTAccess Developer'S Toolkit
ADTAdaptive De-Interlace Technique
ADTArchitectural Desktop
ADTActive Desktop
ADTAutomated Deployment Toolkit
ADTAutomatic Digital Testing
ADTAutocad Desktop
ADTAutomated Distribution Technologies
ADTAbstract Data Type
ADTAleutian Daylight Time (-9 Hours GMT)
ADTActive Duty for Training
ADTAmerican Discovery Trail (proposed multi-use trail across USA)
ADTAgence de Développement Touristique (French: Tourist Development Agency)
ADTAggregate Data Type (computing)
ADTAverage Daily Trips (transportation)
ADTArticulated Dump Truck
ADTAnnual Daily Traffic
ADTAgribusiness Development Team (US DoD)
ADTAdenosine Triphosphate
ADTAutomatic Double Tracking
ADTAdvanced Dicing Technologies (Horsham, Pennsylvania)
ADTAguas del Tunari (Bolivian water regulation)
ADTApplication Development Toolkit
ADTApplication Development Tool
ADTAll-Defensive Team (sports)
ADTActive Denial Technology
ADTAshland Daily Tidings (Ashland, OR)
ADTAerospace and Defense Technology
ADTAdult Day Training
ADTAnti-Discrimination Tribunal (Australia)
ADTAdvantage Data Transformer (CA Technologies)
ADTAdult Diphtheria Tetanus (vaccination)
ADTAstronomy Diagnostic Test
ADTAccess Developer's Toolkit (Microsoft)
ADTAdvanced DRAM Technology
ADTAssociate Dean Teaching (various schools)
ADTAgriculture Development Team (US DoD)
ADTAverage Daily Turnover (stock trading)
ADTApplication Data Types
ADTAmerican District Telegraph Company
ADTAdmissions, Discharge, Transfer (healthcare)
ADTApplication Development Team
ADTActive Duty Tour
ADTArt Design Technology
ADTAided Tracking
ADTAir Dry Ton (cellulose pulp)
ADTAdvanced Data Technologies
ADTAgent Desktop
ADTAlliance Development Trust (relief and development arm of the National Christian Evangelical Alliance of Sri Lanka)
ADTAlaskan Daylight Time (GMT -0800)
ADTAir Data Tester
ADTApplied Data Trends, Inc
ADTApproved Departure Time
ADTAdministrative Delay Time
ADTAccelerated Degradation Testing
ADTAssign Digital Transmission Group
ADTArchitecture Development Team
ADTAir Dissolving Tube
ADTAirborne Data Terminal
ADTAverage Daily Theoretical (casino industry)
ADTAttribute Definition Table
ADTAccumulated Deployed Time
ADTAir Data Transducer
ADTAdmission, Disposition, and Transfer
ADTActive Disk Table
ADTAutomatic Digital Tester
ADTAdvanced Development Team
ADTAssociative Design Technology
ADTAutomated Detection and Tracking
ADTAutomatic Data Translator
ADTAcknowledged Data Transfer
ADTAerated Drain Tank
ADTAdsorbed Diphtheria Tetanus (vaccine)
ADTAtomic Damage Template
ADTAlphanumeric Display Terminal
ADTAutomatic Detection & Tracking
ADTAsset Discovery Tool
ADTArchitectural Development Team
ADTAbnormal Data Type
ADTAverage Download Time
ADTAsynchronous Data Teleservice
ADTAudio Detect Tone
ADTAddress Detector Transition
ADTAnalyst Dependent Technique
ADTAuthorized Dealer Team
ADTAnomaly Detection Tool
ADTAnchorage Daily Times
ADTAnalog Data Tape
ADTAvailable Device Table
ADTAnswer Detection Technology
ADTAlternative Display Technology
ADTAdvanced Dialoguing Techniques
ADTAdvanced Digital Terminal
ADTAccettazione Dismissione Trasferimento (Italian healthcare)
ADTAmerican Dial Tone (Dunedin, FL)
References in periodicals archive ?
Patients were randomized 2:1 to receive ERLEADA in combination with androgen deprivation therapy (ADT) (n=806), or placebo in combination with ADT (n=401).
The results show that the use of XTANDI plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71% compared to ADT alone.
The NDA submission for apalutamide was based on Phase 3 data from the pivotal SPARTAN clinical trial, which assessed the safety and efficacy of apalutamide versus placebo in men with non-metastatic CRPC who have a rapidly rising prostate specific antigen despite receiving continuous androgen deprivation therapy.
This NDA submission for apalutamide was based on the company's Phase 3 data from the pivotal ARN-509-003 (SPARTAN) clinical trial, which assessed the safety and efficacy of apalutamide versus placebo in men with non-metastatic CRPC who have a rapidly rising prostate specific antigen (PSA) despite receiving continuous androgen deprivation therapy (ADT).
ABSTRACT: In 2010, Serpa Neto et al, conducted systematic review and meta-analysis of thirty-two studies and found that patients with prostate cancer who underwent androgen deprivation therapy had lower levels of bone mineral density and higher rates of osteoporosis and fractures compared to patients not undergoing androgen deprivation therapy.
Objective: The objective of this study was to investigate the effects of androgen deprivation therapy (ADT) on risk of subsequent cardiovascular morbidity in men with prostate cancer.
Androgen Deprivation Therapy (ADT) shuts down the body's main supply of the male hormone and is a less drastic alternative to physical castration.
Researchers warn Androgen Deprivation Therapy, which lowers the body's supply of testosterone, can affect brain health.
Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
The December 7, 2015, issue of the Journal of Clinical Oncology published the results of a case-control study that found the risk of Alzheimer's disease was significantly higher among men who were prescribed androgen deprivation therapy for prostate cancer compared to those who did not receive it.
Safar 28, 1437, December 10, 2015, SPA -- Androgen deprivation therapy, or ADT, is one of the primary methods of treating prostate cancer because of the role testosterone plays in tumor growth.
Forgoing androgen deprivation therapy cuts rather than raises overall and cardiac mortality in certain patients with prostate cancer, depending on their comorbidities, according to a Research Letter to the Editor published online Sept.
Full browser ?